Literature DB >> 19597195

Improving health r&d financing for developing countries: a menu of innovative policy options.

Robert Hecht1, Paul Wilson, Amrita Palriwala.   

Abstract

New drugs, vaccines, and diagnostics for the diseases of the developing world could save millions of lives and prevent enormous suffering and economic loss. Despite substantial new funding from the Gates Foundation and other donors, financing for the development of these new health technologies remains inadequate. New approaches are needed to generate more resources, make funding more stable and flexible, and further engage the expertise of the pharmaceutical industry. Several new financing mechanisms have been launched recently, and others are being proposed. This paper summarizes some of the most promising new ideas and offers a framework for evaluating them.

Mesh:

Year:  2009        PMID: 19597195     DOI: 10.1377/hlthaff.28.4.974

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  7 in total

Review 1.  Current progress in the management of rare diseases and orphan drugs in China.

Authors:  Shiwei Gong; Si Jin
Journal:  Intractable Rare Dis Res       Date:  2012-05

2.  Pharmacogenomic technologies: a necessary "luxury" for better global public health?

Authors:  Catherine Olivier; Bryn Williams-Jones
Journal:  Global Health       Date:  2011-08-24       Impact factor: 4.185

3.  The diminished pipeline for medications to treat mental health and substance use disorders.

Authors:  Peggy L O'Brien; Cindy Parks Thomas; Dominic Hodgkin; Katharine R Levit; Tami L Mark
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084

4.  Assessing the population health impact of market interventions to improve access to antiretroviral treatment.

Authors:  Till Bärnighausen; Margaret Kyle; Joshua A Salomon; Brenda Waning
Journal:  Health Policy Plan       Date:  2011-09-13       Impact factor: 3.547

5.  Venture capital on a shoestring: Bioventures' pioneering life sciences fund in South Africa.

Authors:  Hassan Masum; Peter A Singer
Journal:  BMC Int Health Hum Rights       Date:  2010-12-13

6.  First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.

Authors:  Laura W Musselwhite; Karolina Maciag; Alex Lankowski; Michael C Gretes; Thomas E Wellems; Gloria Tavera; Rebecca E Goulding; Ethan Guillen
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

7.  Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.

Authors:  David M Brogan; Elias Mossialos
Journal:  Global Health       Date:  2013-11-07       Impact factor: 4.185

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.